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Background. Methicillin-resistant Staphylococcus aureus (MRSA) infects 25% of patients with cystic
fibrosis (CF) in the United States. We hypothesized that health-related outcomes differed between healthcare-
associated (staphylococcal cassette chromosome mec [SCCmec] II) vs community-associated (SCCmec IV)
MRSA strains in patients chronically infected with CF.
Methods. At 7 CF centers, MRSA isolates were prospectively obtained from patients 18 years old with 2 or
more positive MRSA cultures within 1 year. Isolates were classified by SCCmec type and Panton-Valentine-
leukocidin (PVL) status at a core laboratory, and sites remained blinded to SCCmec type and PVL results.
Prospective clinical data including antibiotic use, respiratory symptoms, and pulmonary exacerbations were
obtained.
Results. Among the 295 cohort participants with typeable MRSA isolates, 69.5% had SCCmec II PVL(−),
13.2% had SCCmec IV PVL(−), and 17.3% had SCCmec IV PVL(+) strains. During follow-up of 287 patients
with prospective data after enrollment, the risk for pulmonary exacerbations was significantly higher among
participants with SCCmec II than SCCmec IV strains (risk ratio [RR] = 1.13; P = .03) and higher in those with
SCCmec IV PVL(−) than SCCmec IV PVL(+) strains (RR = 1.62; P < .0001). Neither decline in lung function nor
changes in nutritional outcomes differed by SCCmec type or PVL status during the study period.
Conclusions. Participants harboring chronic SCCmec II MRSA received more antibiotics and may have more
lung disease than those with SCCmec IV; PVL(+) isolates were not associated with more advanced disease.
Key words. cystic fibrosis; methicillin-resistant Staphylococcus aureus; Panton-Valentine leukocidin;
pulmonary exacerbation; PVL; SCCmec type.
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BACKGROUND
The incidence and prevalence of methicillin-resistant
Staphylococcus aureus (MRSA) has been increasing in pa-
tients with cystic fibrosis (CF) in the United States. By
2010, 25.8% of patients reported to the Cystic Fibrosis
Foundation National Patient Registry had a positive respi-
ratory culture for MRSA [1, 2]. Epidemiologic studies per-
formed in patients with CF have suggested that lung
function may be lower with MRSA compared to
methicillin-susceptible S aureus, and chronic MRSA infec-
tion is associated with increased mortality [3–5] and mor-
bidity [6].
Methicillin resistance is encoded by the staphylococcal
cassette chromosome mec (SCCmec) gene complex. In
general, healthcare-associated strains carry SCCmec types
I–III and are negative for Panton-Valentine leukocidin
(PVL), whereas strains more likely to be community-
associated carry the smaller SCCmec IV–V elements
[7–9]. However, SCCmec types II and IV are increasingly
found in community and hospital settings, respectively
[10–12]. Studies evaluating the molecular epidemiology
of MRSA in patients with CF in the United States have re-
ported approximately two-thirds of MRSA strains were
SCCmec II [13–15]. In non-CF MRSA disease, outcomes
may be different based on SCCmec status [16, 17].
However, outcomes associated with different SCCmec
types have not been addressed in CF patients with chronic
lung infections, and SCCmec status is not currently used in
clinical care. Nonetheless, because SCCmec II encodes for
more antibiotic resistance genes [18, 19], there may be a
poor response to oral antibiotics or choices may be limited;
thus, the question arises whether knowledge of the
SCCmec type would be relevant to care.
We hypothesized that, among children with CF who are
chronically infected with MRSA, outpatient antibiotic use,
exacerbations, and lung function and growth metrics
would differ by SCCmec type and that PVL(+) isolates
would be associated with worse outcomes. We present a
multicenter observational study to evaluate the clinical out-
comes and treatment associated with different SCCmec
types and PVL status in children with CF who have persis-
tently MRSA-positive respiratory tract cultures.
METHODS
Study Design, Participants, and Sites
An observational study was conducted at 7 CF centers
from different regions of the United States between 2008
and 2012. Patients diagnosed with CF [20],18 years of
age, with chronic MRSA infection (2 positive cultures
within at least 1 of the 2 years before enrollment) were
eligible. They were included in the study if their culture
was positive for MRSA at enrollment or at 1 of the 2 sub-
sequent CF clinic visits. Patients who had positive cultures
for Burkholderia cepacia complex or had undergone lung
transplantation were ineligible to participate. Sites were se-
lected based on MRSA prevalence ( >20%) and size ( >200
pediatric patients). The study was approved by each cen-
ter’s Institutional Review Board, written consent was ob-
tained from parents, and assent was obtained from
children able to read.
Typing of MRSA Isolates
Participants’ respiratory cultures (deep pharyngeal swab,
sputum, or bronchoalveolar lavage) were processed at
each site’s clinical microbiology laboratory using the
Cystic Fibrosis Foundation’s guidelines [21]. Three colo-
nies of MRSA from the same culture were sent to the
core laboratory at the University of North Carolina to
determine the SCCmec type and presence of the PVL
gene using polymerase chain reaction methods previously
described [15, 22, 23]. Treating physicians were not
informed about the typing results.
Data Collection
Site investigators prospectively recorded each participant’s
clinic visits from patient entry into the study until April
2012 or for a maximum of 3 years of follow-up. Weight,
height, spirometry as forced expiratory volume in 1 second
(FEV1), and respiratory tract culture results were recorded
at visits when new antibiotics were prescribed (oral, in-
haled, or intravenous [IV]) for respiratory indications.
Spirometry was recorded for those participants older
than 6 years of age and expressed as percentage predicted
per Wang’s equation [24]. Body mass index (BMI) percen-
tile (in participants 2 years of age or older) or weight for
length percentile (in participants less than 2 years of age)
according to US standards [25, 26] were recorded.
Organisms other than S aureus present in the respiratory
tract cultures were collected, but antibiotic susceptibility
patterns were not recorded for any CF pathogens.
Antibiotic use was collected for oral, inhaled, and IV anti-
biotics. Oral antimicrobial agents included trimethoprim-
sulfamethoxazole (TMP-SMX), fluoroquinolone agents,
linezolid, tetracycline, rifampin, clindamycin, and other
agents without activity against MRSA (eg, amoxicillin).
The presence of specific signs and symptoms were col-
lected at the time of prescribing a new antibiotic to evaluate
whether the event qualified as a study-defined pulmonary
exacerbation [27,28]. In brief, an exacerbation was defined
as receiving new antibiotic treatment plus 1 or 2 of the 2
major criteria (10% decrease in FEV1 from 6-month
baseline, or oxygen saturation <90%, or 5% decline) or
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2 or more of the 8 minor criteria (new or increased: cough,
fatigue, chest congestion or sputum, respiratory symptoms
or adventitial sounds; decreased: activity, appetite, or
weight). Clinical study data were linked with the following
data from the US Cystic Fibrosis Patient Registry: demo-
graphic characteristics, CF transmembrane regulator
(CFTR) genotype, MRSA culture dates, and other microbi-
ology results before enrollment, and spirometry and BMI
collected for the duration of the study.
Statistical Analyses
Demographic characteristics and clinical data were de-
scribed using summary statistics and compared among par-
ticipants with different SCCmec types and PVL status using
2-sided, 0.05 alpha level t tests for continuous variables or
Fisher’s exact test for categorical variables. Cystic fibrosis
clinic visits, antibiotic use, symptoms, and pulmonary ex-
acerbations (defined above) were analyzed following en-
rollment by SCCmec type and PVL status. Oral antibiotic
agents were summarized and compared as percentage of
oral prescriptions, overall use, and use at the center level.
Repeated measures analysis of covariancewas used to com-
pare FEV1% predicted, BMI (or weight for length) percen-
tile, and symptoms corresponding to antibiotic treatment
adjusted for sex, age at first study visit, time since MRSA
onset, study site, and presence of Pseudomonas aeruginosa
at time of study enrollment. All available FEV1% predicted
and anthropometric percentile data from the Patient
Registry were modeled linearly with a compound symmet-
ric correlation structure. Pulmonary exacerbations were
modeled as rate per year using Poisson regression adjusted
for aforementioned covariates to estimate risk ratio (RR)
estimates and 95% confidence intervals (CIs). SAS version
9.2 (SAS Institute, Cary, NC) was used for all analyses.
RESULTS
FromOctober 2008 to April 2010, 314MRSA-positive pa-
tients with a history of chronic MRSA infection were re-
cruited from 7 CF centers. Of these, 295 participants had
typeable MRSA isolates: 205 (69.5%) SCCmec II all PVL
(−), 39 (13.2%) SCCmec IV PVL(−), and 51 (17.3)%
SCCmec IV PVL(+). The final study population consisted
of 287 participants for whom the date of first detection
of MRSA was available in the Cystic Fibrosis Patient
Registry, and prospective study data were collected.
Participant Characteristics by MRSA Type
Mean age, sex, CFTR genotypes, lung function (FEV1%
predicted), and nutritional status (BMI or weight for length
percentile) were similar in participants with SCCmec II vs
SCCmec IVMRSA type and among those with SCCmec IV
PVL(+) and SCCmec IV PVL(−) isolates (Table 1).
However, there were more participants12 years of age
infected with SCCmec II isolates. A greater percentage of
participants with SCCmec II isolates had P aeruginosa-
positive cultures at study enrollment (30.2% compared
to 19.3% in SCCmec type IV), but the difference was not
statistically significant (P = .056).
Most (71%) of the participants had 2 or more years of
prospective follow-up; 91% (n = 261) had 1 year or more
of follow-up, and 3.8% (n = 11) had only data collected
during the enrollment visit. Duration of follow-up was
comparable for participants with SCCmec II and
SCCmec IV (mean [standard deviation; SD] = 2.2 [0.71]
vs 2.1 [0.75] years, respectively; P = .15). At the time of en-
rollment, participants with SCCmec II had significantly
longer duration of MRSA infection than those with
SCCmec IV (mean = 4.7 [3.1] and 3.1 [2.5] years,
Table 1. Participant Characteristics by MRSA Type at Time of Study Enrollment
Characteristic SCCmec II SCCmec IV P Value SCCmec IV SCCmec IV P Value
N = 199 N = 88 PVL(+)N = 50 PVL(−)N = 38
Female n (%) 102 (51.3%) 37 (42.1%) 0.16 21 (42.0%) 16 (42.1%) 1.0
Age in years Mean (SD) 11.5 (4.6) 10.3 (5.0) 0.40 10.0 (5.2) 10.7 (4.6) 0.41
Age group n (%)
<6 years 31 (15.6%) 16 (18.2%) 0.03* 11 (22.0%) 5 (13.2%) 0.63a
6–11 years 65 (32.7%) 41 (46.6%) 22 (44.0%) 19 (50.0%)
12 years 103 (51.8%) 31 (35.2%) 17 (34.0%) 14 (36.8%)
CFTR genotype n (%)
F508 del homozygous 113 (56.8%) 43 (48.9%) 0.52* 27 (54.0%) 16 (42.1%) 0.39a
F508 del heterozygous 71 (35.7%) 36 (40.9%) 18 (36.0%) 18 (47.4%)
Other 10 (5.0%) 7 (8.0%) 3 (6.0%) 4 (10.5%)
Not done/missing 5 (2.5%) 2 (2.3%) 2 (4.0%) 0 (0%)
Pseudomonas aeruginosa n (%) 60 (30.2%) 17 (19.3%) 0.056 12 (24.0%) 5 (13.2%) 0.20
BMI or Wt/length Percentile† n: mean (SD) 176: 44.3 (27.3) 79: 46.4 (29.8) 0.34 44: 41.2 (30.1) 35: 53.0 (28.5) 0.75
FEV1% predicted
‡ n: mean (SD) 141: 81.9 (22.0) 64: 81.7 (22.5) 0.82 34: 77.9 (22.7) 30: 85.9 (21.9) 0.16
Abbreviations: BMI, body mass index; CFTR, cystic fibrosis transmembrane regulator; FEV1, forced expiratory flow in 1 second; MRSA, methicillin-resistant
Staphylococcus aureus; PVL, Panton-Valentine-leukocidin; SCCmec, staphylococcal cassette chromosome mec; SD, standard deviation; Wt/length, weight for length.
*P value for Fisher’s test of distributional differences between groups.
†For children <2 years of age, weight for length is used in place of BMI.
‡FEV1% predicted is recorded only in participants >6 years of age (see Methods).
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respectively; P < .001). Among those with SCCmec IV iso-
lates, the duration of time since initial detection of MRSA
was longer in those with PVL(−) isolates (mean = 4.0 [3.0]
years) than PVL(+) isolates (mean = 2.4 [1.9] years)
(P < .01).
Clinic Visits and Antibiotic Treatment
The number of CF clinic visits and the rate of antibiotic
prescriptions by SCCmec type and PVL status are de-
scribed in Table 2. For all participants with MRSA, the
mean number of clinic visits was 6.0 (SD = 2.9) visits per
year and ranged from 1 to 62 clinic visits per participant
during the study period. Participants with SCCmec IV
PVL(−) isolates had more CF clinic visits per participant
and per year of follow-up than those with SCCmec IV
PVL(+) isolates.
Antibiotics (oral, additional inhaled or IV) were pre-
scribed at 58.1% of all CF clinic visits in association
with increased signs and symptoms. Oral agents were
most common and were prescribed at 45.8% of visits
(46.9% of visits of participants with SCCmec II isolates
compared to 42.9% of visits of participants with
SCCmec IV isolates; P = .025). Overall, the oral antibiotics
TMP-SMX, fluoroquinolone agents, and linezolid were
most frequently prescribed. Linezolid was used more
often in those with SCCmec II (23.2%) compared to
SCCmec IV (18.2%) isolates (P = .01) (range per center,
5.6%–34.8%). A single oral antibiotic was prescribed for
72.8% of treatment events, dual therapywas prescribed for
24.0%, and 3 or more agents were prescribed for 3.2% of
events. Rifampin and clindamycin were rarely prescribed.
Agents without MRSA activity were prescribed in approx-
imately 7% of treatment events.
Symptoms were recorded at 85.6% of visits in which
new antibiotics were prescribed. The number of symptoms
was similar for participants with SCCmec II vs SCCmec IV
isolates (mean [SD] 3.02 [1.99] vs 2.89 [2.01], respectively,
adjusted; P = .68). The number of symptoms among
SCCmec IV PVL(−) vs PVL(+) isolates was also similar
(mean [SD] = 3.01 [2.05] vs 2.76 [1.95], respectively,
adjusted; P = .67).
Pulmonary Exacerbations
Study criteria for a pulmonary exacerbation were met in
77.0% of events for which treating clinicians prescribed
antibiotics. The annual rate of study-defined exacerbations
was higher in thosewith SCCmec II isolates than thosewith
SCCmec IV isolates (2.9 [95% CI, 2.7–3.0] vs 2.4 [95%
CI, 2.2–2.6], respectively; P = .0003). After adjusting for
sex, age at first MRSA detection, time since initial MRSA
detection, study site, and presence of P aeruginosa, the risk
for pulmonary exacerbations remained significantly higher
among those with SCCmec II than among those with
SCCmec IV isolates (adjusted RR = 1.13 [95% CI, 1.01–
1.27]; P = .03). Among participants infected with
SCCmec IV isolates, the rate of exacerbations was higher
in those with PVL(−) isolates than those with PVL(+) iso-
lates (annual rate 2.8 [95% CI, 2.5–3.2] vs 2.0 [95% CI,
1.7–2.3], respectively; P = .0002). The adjusted risk for ex-
acerbations remained significantly higher among those
with PVL(−) isolates (RR = 1.62 [95% CI, 1.28–2.04];
P < .0001).
Lung Function and Growth
Using all spirometry recorded in the National Patient
Registry for the duration of the study (independent of an-
tibiotic usage), the estimated annual rate of decline in











(N = 38) P Value
Clinic visits/participant Mean (SD) 13.3 (7.6) 11.8 (7.6) .15 9.9 (4.5) 14.3 (9.9) .014
Clinic visits/year follow-up Mean (SD) 6.1 (3.0) 5.8 (2.6) .40 5.3 (2.0) 6.4 (3.1) .05
Visits with inhaled, oral, or IV
antibiotics prescribed
n (%) 1642 (60.6%) 549 (51.8%) <.001 271 (50.1%) 278 (53.4%) .28
Prescriptions of TMP-SMX* % 33.0 35.0 .37 31.0 39.2 .049
Prescriptions of
fluoroquinolone*
% 23.4 25.9 .25 22.9 28.8 .12
Prescriptions of linezolid* % 23.2 18.2 .01 20.7 15.8 .15
Prescriptions of tetracycline* % 8.6 7.3 .37 11.4 3.2 <.001
Prescriptions of rifampin* % 4.7 3.8 .47 5.6 2.2 .046
Prescriptions of clindamycin* % 0.2 1.6 <.001 0.7 2.5 .18
Prescriptions of non-MRSA
active oral antibiotic*,†
% 6.9 8.0 .39 7.8 8.3 .88
Abbreviations: IV, intravenous; MRSA, methicillin-resistant Staphylococcus aureus; PVL, Panton-Valentine-leukocidin; SCCmec, staphylococcal cassette chromosome
mec; SD, standard deviation; TMP-SMX, trimethoprim-sulfamethoxazole. Bold text indicates P Value <0.05.
*Expressed as a percentage of oral antibiotics prescribed.
†These were antibiotics classically not considered active for MRSA (eg, amoxicillin).
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FEV1% predicted was not significantly different between
SCCmec types (P = .73): −1.8% (95% CI: −3.5, −0.1) for
SCCmec II compared to −1.2% for SCCmec IV (95% CI:
−4.1, 1.7) adjusted for sex, age at first study visit, time since
MRSA onset, study site, and presence of P aeruginosa.
Among those with SCCmec IV, PVL was not associated
with differing rates of decline in FEV1% predicted
(P = .88).
Likewise, changes in BMI/weight for length percentile
did not differ between the SCCmec types (P = .74):
−0.6% per year (95% CI: −2.9, 1.9) for SCCmec II com-
pared to −1.3% per year for SCCmec IV (95% CI, −5.1,
2.5). Body mass index/weight for length percentile per
year did not differ by PVL status (P = .97).
DISCUSSION
This is the first multicenter study to analyze the association
between chronic infection with different MRSA SCCmec
types with clinical outcomes in patients with CF. At the
time of enrollment into this study, those participants with
SCCmec II isolates were older, had a longer duration of
MRSA infection, and were more likely to be coinfected
with P aeruginosa. We demonstrated that, when adjusting
for these and other covariates known to impact CF lung
disease, the rate of exacerbations was higher in participants
with SCCmec II isolates compared to those with SCCmec
IV isolates. Furthermore, among those with SCCmec IV
isolates, the rate of exacerbations was higher in those
with PVL(−) isolates than those with PVL(+) isolates.
Likewise, the number of CF clinic visits per participant
and per year of follow-up was greater in those infected
with PVL(−) isolates. Notably, treating clinicians did not
know the SCCmec type infecting their patients; thus, treat-
ment decisions were made without consideration of MRSA
type. Forty-four percent of our SCCmec IV isolates were
PVL negative, which allowed comparison within this
group by PVL status. Previous reports in CF showed
worse presentation at MRSA onset in PVL(+) MRSA iso-
lates in a case series [29]. Furthermore, PVL has been pos-
tulated to be the cause of necrotizing pneumonia in
previously healthy people [30]. However, these earlier ob-
servations have been questioned in other studies [18]. Our
findings do not lend support to PVL(+) isolates causing
worse disease in patients with CF.
Although an observational study cannot determine cau-
sality, there are several possible explanations for the differ-
ent outcomes related to PVL status and SCCmec type.
Contrary to our hypothesis that PVL positivity would be
associated with worse outcomes, we found that SCCmec
IV PVL(−) and SCCmec II [all PVL(−)] isolates were
associated with more overall CF clinic visits and with
more visits at which antibiotics were prescribed, respective-
ly. These outcomes may be affected by bacterial and host
aspects in a multifactorial manner. Bacterial factors related
to S aureus type with potential impact include antibiotic
susceptibilities, virulence factors, or bacterial fitness.
Although some non-CF studies show that a higher
vancomycin minimal inhibitory concentration has been
associated with worse outcomes [31], we did not see
vancomycin-resistant or vancomycin-intermediate isolates
in this study [22].Other bacterial factors were not assessed
in this study and would only be speculative. In addition,
outcomes observed here may be related to host characteris-
tics rather than bacterial virulence. Observational studies
of invasive MRSA infections in the United States have re-
ported that the underlying disease severity of the infected
individual, rather than the SCCmec type, was the main
risk factor associated with mortality [17, 32].
We had hypothesized that the greater number of antibi-
otic resistance genes in SCCmec II MRSAwould impact the
choice of antibiotic therapy used to treat pulmonary exac-
erbations. We have previously shown that the SCCmec II
strains were more often resistant to clindamycin and cipro-
floxacin compared with the SCCmec IV strains [22]. We
found that linezolid was used more often in those with
SCCmec type II compared to SCCmec IV, which may be re-
flective of these differences in antimicrobial susceptibilities.
However, this antibiotic should be used with caution
because resistance can emerge [33–35], and it may be asso-
ciated with potentially irreversible side effects including pe-
ripheral neuropathy. Our study definition of exacerbations
included the use of oral agents as well as IV antibiotics; this
definition allowed assessment of all exacerbations and re-
duced the potential bias toward more severe events and
only very resistant isolates, which were expected to be
more frequent in SCCmec II strains.
We acknowledge some limitations of this study. First,
only 1 culture was used for classification of MRSA type;
however, previous studies, including our own, have
shown persistence of the same strain over time [36–38].
In addition, although this was a multicenter study, inclu-
sion was limited to children, and it is unknown whether
these findings are generalizable to adults, or to CF centers
that have a prevalence of MRSA less than 20%, or to chil-
dren with CF outside the United States, where different
strains may be prevalent. Duration of follow-up was vari-
able for the participants; however, there were not signifi-
cant differences between groups, and our analysis
accounted for follow-up duration; therefore, results are
unlikely biased. Longitudinal spirometry and weight
for length/BMI were compared, and no differences by
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SCCmec type or PVL were observed, despite differences in
pulmonary exacerbations. We speculated that these obser-
vations may reflect several factors related to this study de-
sign and population. The FEV1% predicted and BMI
percentiles in the Patient Registry had high a within-patient
variation. In addition, 16% of the population was too
young to reliably perform spirometry at study entry, where-
as they were included in the exacerbation analysis.
Furthermore, published studies of the association between
lung function decline and exacerbations typically define ex-
acerbations as events when IV antibiotics were used. In this
study, however, exacerbations were also defined when oral
antibiotics were used, which may have prevented lung
function decline. The estimated rate of FEV1 decline in
this cohort was consistent with previously reported de-
clines in lung function among CF patients persistently in-
fected with MRSA [5]. Another possible source of bias is
the fact that patient signs and symptoms were only collect-
ed when new antibiotics were prescribed, both to limit re-
porting burden to the sites and because we considered
symptoms not associated with treatment to be relatively
minor in scope. However, in this pediatric population,
there may be an overall lower threshold for treating as
seen by use of antibiotics in 23% of cases that did not
meet exacerbation criteria. Lastly, we chose not to collect
antibiotic susceptibilities for isolates tested at each visit
and each study site to avoid variation in techniques and re-
sults; thus, study outcomes were not analyzed by success or
failure of antibiotic course.
CONCLUSIONS
In conclusion, we show that children with CF chronically
infected with SCCmec II MRSA isolates have higher exac-
erbation rates and use of oral antibiotics compared with
those with SCCmec IV and that PVL(+) status was not as-
sociated with worse outcome. Although an epidemiologic
study cannot address causality of higher exacerbation
rates, our results do raise the following questions: (1)
would routine clinical typing be advantageous to clinicians
treating patients chronically infected with MRSA? and (2)
are further, prospective studies that include subtyping war-
ranted? The answers to these questions could allow us to
more precisely direct care and to determine whether an
eradication strategy should be favored based on S aureus
type. Currently, data showing the benefit of early eradica-
tion for anyMRSA type in CF are not available, but studies
examining the clinical effect of eradication are in progress.
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